Ahmet Ozen | Pediatric Allergy and Immunology | Best Researcher Award

Posted on by ScienceFather

Prof. Ahmet Ozen | Pediatric Allergy and Immunology | Best Researcher Award

Professor, Marmara University Turkey

Dr. Ahmet Özen is the Chief of the Division of Allergy and Immunology in Pediatrics at Marmara University and Director of the Istanbul Jeffrey Modell Center for Primary Immune Deficiencies. A distinguished researcher, he is renowned for discovering genetic mutations linked to immune dysregulation and CHAPLE disease, leading to FDA approval of pozelimab. With a career dedicated to translational medicine, Dr. Özen founded the Marmara University Işıl Berat Barlan Center for Translational Medicine and plays an active role in the NIAID-MENAT Strategy for Enhanced Research Engagement Program. His groundbreaking work on monogenic IBD networks in Türkiye has shaped new therapeutic pathways, benefiting countless patients globally.

Publication Profile

Google Scholar

🎓 Education

M.D. in Medicine, Marmara University, Istanbul (2000) Residency: Pediatrics, Marmara University (2005) Fellowship: Pediatric Allergy and Immunology, Yeditepe University (2012). Postdoctoral Research: Lab of Immunology, NIAID, NIH, Bethesda, MD (2016) Dr. Özen’s educational journey spans prestigious institutions, where he developed expertise in immunology, pediatrics, and translational medicine. His NIH fellowship catalyzed significant research in immune dysregulation and CHAPLE disease.

💼 Experience

2016–Present: Chief, Division of Allergy & Immunology, Marmara University. 2016–Present: Director, Istanbul Jeffrey Modell Center. 2020–Present: Founder, Işıl Berat Barlan Center for Translational Medicine Dr. Özen’s professional roles reflect leadership in clinical care, research, and education. His transformative contributions to pediatric immunology, particularly through international collaborations, have advanced global health initiatives.

🏆 Awards & Honors

2021: EFIS Diversity Task Force Publication Award. 2021: Turkish Council of Higher Education Award for Excellence in International Collaborations. 2022: Aziz Sancar Award, Health Institutes of Türkiye. 2024: EFIS Eastern Star Award Dr. Özen’s accolades recognize his outstanding achievements in immunological research, collaborations, and pioneering clinical applications.

🔬 Research Focus

Dr. Özen specializes in immune dysregulation, monogenic IBD, and CHAPLE disease. His work includes identifying gene mutations (e.g., CD55, IL37, ST6Galnac1), exploring complement hyperactivation pathways, and developing targeted therapies. His contributions to translational medicine and precision therapy have set benchmarks in pediatric allergy and immunology.

Conclusion

Dr. Özen’s unparalleled achievements in pediatric immunology, combined with his visionary leadership, make him an exemplary researcher deserving of recognition. His commitment to translating complex immunological findings into therapeutic innovations underscores his profound influence on the field. Recognizing Dr. Özen with the Best Researcher Award would not only honor his past accomplishments but also inspire continued excellence and advancement in pediatric allergy and immunology research.

Publication Top Notes

  1. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study
    • Year: 2021
    • Authors: I Meyts, G Bucciol, I Quinti, B Neven, A Fischer, E Seoane, …
    • Citation: 369
  2. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European Society for Immunodeficiencies-activated phosphoinositide 3-kinase δ study
    • Year: 2018
    • Authors: ME Maccari, H Abolhassani, A Aghamohammadi, A Aiuti, O Aleinikova, …
    • Citation: 320
  3. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K
    • Year: 2014
    • Authors: CL Lucas, Y Zhang, A Venida, Y Wang, J Hughes, J McElwee, M Butrick, …
    • Citation: 303
  4. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study
    • Year: 2018
    • Authors: F Barzaghi, LCA Hernandez, B Neven, S Ricci, ZY Kucuk, JJ Bleesing, …
    • Citation: 284
  5. Clinical and metabolic features of urolithiasis and microlithiasis in children
    • Year: 2009
    • Authors: H Alpay, A Ozen, I Gokce, N Biyikli
    • Citation: 239
  6. A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity
    • Year: 2018
    • Authors: V Béziat, J Li, JX Lin, CS Ma, P Li, A Bousfiha, I Pellier, S Zoghi, S Baris, …
    • Citation: 185
  7. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis
    • Year: 2017
    • Authors: A Ozen, WA Comrie, RC Ardy, C Domínguez Conde, B Dalgic, ÖF Beser, …
    • Citation: 183
  8. Abatacept as a long-term targeted therapy for LRBA deficiency
    • Year: 2019
    • Authors: A Kiykim, I Ogulur, E Dursun, LM Charbonnier, E Nain, S Cekic, …
    • Citation: 160
  9. Mucus sialylation determines intestinal host-commensal homeostasis
    • Year: 2022
    • Authors: Y Yao, G Kim, S Shafer, Z Chen, S Kubo, Y Ji, J Luo, W Yang, SP Perner, …
    • Citation: 156
  10. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes
    • Year: 2011
    • Authors: S Keles, E Karakoc-Aydiner, A Ozen, AG Izgi, A Tevetoglu, T Akkoc, …
    • Citation: 151

 

Daniela Malengo | Pharmacology | Women Researcher Award

Posted on by ScienceFather

Dr. Daniela Malengo | Pharmacology | Women Researcher Award

Dr at Istituto Europeo di Oncologia, Italy

Daniela Malengo, an Italian pharmacist, is currently the Vice Director of the Hospital Pharmacy Division at Istituto Europeo di Oncologia, Milan. With a career spanning over 15 years, Daniela specializes in oncology drug management, hospital pharmacy administration, and medical device protocols. She is passionate about optimizing pharmaceutical practices and contributing to oncology care. Throughout her career, she has been dedicated to ensuring the safe and effective use of drugs in oncological treatments and has supported numerous research projects. Her leadership skills also extend to teaching pharmacy students through internships and projects.

Profile

Scopus

🎓 Education 

Management of CAR-T Patients, LIUC Business School (Dec 2023–Mar 2024). Hospital Pharmacy Management, Università Bocconi, Milan (Sept 2019–Dec 2020). Specialization in Applied Pharmacology, University of Pavia (2005–2009). Degree in Pharmacy, University of Pavia (2000–2005). State Exam for Pharmacist License, University of Pavia (Nov–Dec 2005). Scientific High School Diploma, Liceo Scientifico N. Copernico, Pavia (1995–2000)

💼 Experience

Vice Director of Hospital Pharmacy Division, Istituto Europeo di Oncologia, Milan (July 2023–Present): Managing narcotic drug dispensation and overseeing oncological therapy. Assistant Pharmacist, Istituto Europeo di Oncologia, Milan (Mar 2011–July 2023): Managed medical devices and chemotherapy prescriptions. Pharmacist – Research Fellow, Istituto Europeo di Oncologia, Milan (May 2006–Feb 2011): Supervised experimental drugs and contributed to research on oncological drug appropriateness. Intern (2004–2005): Worked at Farmacia Dott. A. Lodola, Siziano, dispensing medications to the public.

🏆 Awards & Honors

Numerous presentations at national congresses, including SIFO Congress (2009–2010). Recognized for contributions to hospital pharmacy management and cost analysis of oncological treatments. Leadership roles in pharmacy student internships and research programs. Awarded for excellence in promoting safe oncological drug usage.

🔬 Research Focus

Oncology Pharmacology: Focuses on managing oncological drug appropriateness, chemotherapy prescriptions, and medical device protocols. Pharmacy Management: Expertise in hospital pharmacy operations, including drug dispensation, quality control, and patient safety. Experimental Pharmacology: Managed experimental drugs and contributed to clinical research in oncological treatments. Cost Analysis: Focus on managing hospital pharmacy expenses and evaluating drug cost-effectiveness.

Conclusion

Daniela Malengo’s career exemplifies dedication to hospital pharmacy, oncological drug management, and the advancement of healthcare systems through her research and leadership roles. Her consistent contributions to improving patient outcomes in oncology, coupled with her academic excellence, make her a strong candidate for the Women Researcher Award. With her continued focus on improving the quality of healthcare services and mentoring future professionals, Daniela’s future contributions are poised to have a lasting impact in both the pharmacy and healthcare sectors.

📚Publications 

  • The Prolonged Clinical Benefit with Metronomic Chemotherapy (VEX Regimen) in Metastatic Breast Cancer Patients
    • Authors: Montagna, E., Pagan, E., Cancello, G., Viale, G., Colleoni, M.
    • Journal: Anti-Cancer Drugs
    • Volume: 33
    • Issue: 1
    • Pages: E628–E634
    • Year: 2022
    • Citations: 6

 

  • Management of Breast Cancer Patients During the Peak of the COVID-19 Pandemic
    • Authors: Montagna, E., Bellerba, F., Sangalli, C., Colleoni, M., Veronesi, P.
    • Journal: European Journal of Surgical Oncology
    • Volume: 47
    • Issue: 10
    • Pages: 2694–2695
    • Year: 2021
    • Citations: 2